

Special Issue

Indole Derivatives as Targeted Melatonin and Serotonin Receptor Ligands

Message from the Guest Editors

Indole derivatives and relative bioisosteres, including other condensed heteroaryl scaffolds or simplified derivatives with a flexible chain, represent the principal strategy to design compounds with melatonergic or serotonergic activity through structure–activity relationship studies. In this Special Issue, we want to highlight the newest findings in the discovery of synthetic or natural products with potential bioactivity in target-mediated interaction with melatonin or serotonin receptors. This activity may be complemented by the intrinsic reactivity of compounds due to their antioxidant and radical-scavenging properties or the introduction of a second moiety, resulting in a dual-target or multi-target engagement. We invite you to share recent advancements in the drug design and discovery, synthesis and characterization of new melatonergic or serotonergic compounds containing an indole moiety or a bioisostere replacement. Such new molecules could introduce a novel series, expand our knowledge of already-proposed scaffolds or elucidate new biological activities for known melatonergic or serotonergic agents.

Guest Editors

Dr. Michele Retini

Department of Biomolecular Sciences, University of Urbino “Carlo Bo”,
61029 Urbino, Italy

Dr. Gian Marco Elisi

Department of Biomolecular Sciences, University of Urbino “Carlo Bo”,
61029 Urbino, Italy

Deadline for manuscript submissions

closed (23 February 2025)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/213597

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)